ACS Medicinal Chemistry Letters · 2020 · 21 citations · 6 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyVirologyAntiviral PharmacologyAntiviral TherapyMolecular DockingViral AssemblyViral HepatitisViral Hepatitis TreatmentAntiviral Drug DesignAntiviral Structure-activity RelationshipsDocking StudiesHepatitis B Virus ReplicationMolecular Docking AnalysisViral Capsid AssemblyViral Replication ControlVirus Capsid Assembly
Hepatitis B virus (HBV) remains a major health concern with 260 million people having been infected globally, and approximately 680,000 deaths have occurred annually from cirrhosis and liver cancer. The modulation of HBV capsid assembly has emerged as a promising therapeutic approach for curing chronic HBV infection. Small-molecule capsid assembly modulators (CAMs) can broadly be classified as heteroaryldihydropyrimidines and sulfamoylbenzamides (SBAs). SBAs are capsid activators that inhibit viral replication by achieving capsid assembly before polymerase encapsulation. Herein, we report a novel series of HBV CAMs based on NVR 3-778, a potent CAM belonging to the SBA class. The lead compound (KR-26556) exhibited improved pharmacological activity and was examined through molecular docking studies.
6
AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault, Natalie Bzowej, Kyong‐Mi Chang et al. · Hepatology · 2015 · 2K citations